US EditionPublished • loading... • Updated
Transgene Expands Its Financial Visibility at the Beginning of 2028, but by Diluting Its Shareholders
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biotech raises €105 million as part of a capital increase, which dilutes shareholders who will not participate by 44%. The Mérieux Institute covers 76% of the operation and sees its shareholding rise from 69% to 72%.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
